Could a Two-Drug punch shrink melanoma before surgery?

NCT ID NCT04139902

First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 21 times

Summary

This study tests whether giving a combination of two immunotherapy drugs (dostarlimab and cobolimab) before surgery works better than one drug alone for people with stage III or IV melanoma that can be removed. The goal is to see if the combo can shrink or kill more of the tumor before surgery. About 48 adults with operable melanoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC Hillman Cancer Center Washington

    Washington, Pennsylvania, 15301, United States

Conditions

Explore the condition pages connected to this study.